A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

NCT00042302 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage IIIb Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

PROCEDURE: Chemotherapy
DRUG: tariquidar + paclitaxel/carboplatin
DRUG: placebo + paclitaxel/carboplatin

Sponsor

QLT Inc.